London · Delayed Price · Currency is GBP · Price in GBX Arecor Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
AT278, an ultra-concentrated, ultra-rapid insulin, targets unmet needs in AID systems, with phase II trials planned and a $3–5 billion U.S. market opportunity. The company is also advancing an oral peptide delivery platform, aiming to improve GLP-1 bioavailability and expand partnerships.
Fiscal Year 2025
-
Revenue and cash position improved, supported by a $11M non-dilutive financing and reduced expenses. AT278 insulin and oral peptide delivery platforms advance, with phase II trials and key data expected in 2026. Strategic partnerships and a strong cash runway support growth.
-
Strong progress on strategic R&D focus, highlighted by a co-development deal for AT278 with Sequel MedTech and a royalty financing agreement with Ligand, extends cash runway into H1 2027. Revenue remains steady, costs are controlled, and key clinical and platform milestones are on track.
-
Operations at Tetris Pharma will cease following a strategic review, with Ogluo rights returned to Xeris due to rising costs and reduced margins. Focus shifts to proprietary insulin and oral peptide programs, with inventory sell-through expected to fund future growth.
Fiscal Year 2024
-
Revenues grew 11% to $5.1M, driven by AT220 royalties and Tetris products, while R&D costs fell. AT278 and AT247 showed clinical superiority, and the oral peptide platform advanced, with strong IP and new partnerships supporting future growth.
-
Revenue grew 20% year-over-year, driven by proprietary and partnered products, with AT278 showing superior clinical results and Ogluo expanding in key markets. A recent £6.4 million fundraise extends the cash runway to 24 months, supporting R&D and commercial growth.
-
H1 2024 saw revenue growth from diversified streams, a strengthened balance sheet after a GBP 6.4m fundraise, and clinical advances in diabetes and obesity. AT278 showed best-in-class results, driving strong interest from partners, while Ogluo faces a short-term packaging issue.